Neo7Bioscience

Neo7Bioscience works by translating a patient’s real-time molecular data into a custom-engineered, multi-target peptide formulation. Rather than relying on standardized drugs or off-the-shelf peptide stacks, Neo7Bioscience maps multiple layers of active biology to build a prescription tailored to a single person's immune profile and cellular signaling.

Multi-Omic Data Collection


The process begins with a licensed physician collecting biological samples—typically blood and urine, along with tumor tissue when available.  Instead of looking at a single genetic marker, Neo7Bioscience evaluates five distinct biological layers together:


  • Genomics (Whole-Exome Sequencing). Maps your baseline DNA blueprint to identify inherited vulnerabilities and genetic mutations.


  • Circulating Cancer Signals (ctDNA/cfDNA). Detects active tumor-derived DNA fragments and mutations circulating in the bloodstream when oncology profiling is needed.


  • Transcriptomics (RNA Sequencing). Measures which genes are actively turned on or off right now, showing real-time pathway activity rather than static genetic risk.


  • Proteomics. Analyzes downstream protein activity in blood and urine to reveal active tissue stress, inflammation, and cellular repair.



  • HLA Phenotyping. Maps your Human Leukocyte Antigen (HLA) profile, which acts as the cellular "display system" your immune cells use to recognize targets.

Target Selection & Peptide Engineering

Once the lab data is generated, Neo7Bioscience’s scientific team and proprietary Precision-Based Immuno-Molecular Augmentation (PBIMA) platform analyze how these biological layers interact.


  • Prioritizing Targets. The AI identifies interconnected signaling breakdowns—such as pathways driving tumor growth, immune evasion, or chronic inflammation—and ranks the highest-priority molecular targets.


  • HLA-Informed Matching. For immune-focused applications (such as its ITI-PES cancer technology), peptides are specifically engineered to bind to your exact HLA genotype. Designs often pair an HLA Class II helper antigen with an HLA Class I target to stimulate a coordinated CD4⁺ and CD8⁺ T-cell response.


  • Multi-Target Pooling. Depending on the program, a single formulation combines multiple custom sequences into one pooled therapy—typically 10 to 14+ targets for cancer and complex active diseases, or 4 to 6 targets for post-viral recovery and longevity.



  • Non-Gene-Editing Mechanism. The peptides do not alter or edit your DNA. Instead, they act as precision biological messengers designed to interrupt faulty protein-protein interactions and train the immune system to recognize abnormal cells.

Key Therapeutic & Biological Benefits


  • True N-of-1 Personalization. Two people with the exact same diagnosis can have completely different underlying cellular drivers. Neo7Bioscience designs custom peptide sequences specifically for one individual's active RNA, protein, and mutation signals rather than using generic peptide stacks.


  • Multi-Target Coverage. Complex conditions like cancer and autoimmune disorders rarely rely on a single pathway. Combining 4 to 14+ distinct targets into a single pooled therapy allows physicians to address immune recognition, inflammation, and cellular repair simultaneously.


  • HLA-Matched Immune Precision. By matching peptide sequences to a patient's specific Human Leukocyte Antigen (HLA) profile, the therapy is engineered to fit the immune system's natural presentation machinery. This helps T-cells recognize abnormal or tumor cells that might otherwise evade detection.



  • Non-Gene-Editing & Non-Immunosuppressive. The peptides act as targeted biological messengers to rebalance faulty signaling without altering your DNA or suppressing your broader immune system.

Call us today at 573-636-3995 to schedule a free new patient consultation over the phone.